Brief: Phasebio Announces First Patient Dosed In Phase 2B Clinical Trial Of PB2452 For Reversal Of The Antiplatelet Activity Of Ticagrelor
15/10/2019 13:07
Oct 15 (Reuters) - PhaseBio Pharmaceuticals Inc PHAS.O :
* PHASEBIO ANNOUNCES FIRST PATIENT DOSED IN PHASE 2B
CLINICAL
TRIAL OF PB2452 FOR REVERSAL OF THE ANTIPLATELET ACTIVITY OF
TICAGRELOR
Source text for Eikon: ID:nGNX1PHdyg
Further company coverage: PHAS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PhaseBio Pharmaceuticals
See all newsBrief: Phasebio Pharmaceuticals Says Bankruptcy Court Entered Order Approving 1st Amended Combined Disclosure Statement & Chapter 11 Plan On Final Basis
U.S. RESEARCH ROUNDUP- Entegris, FedEx, Kellogg
U.S. RESEARCH ROUNDUP- Armstrong World Industries, Eli Lilly, Netflix
U.S. STOCKS ON THE MOVE-TransDigm, Vaxcyte, Tricida
PhaseBio Pharma slips on bankruptcy plans